| HS Code | 398424 |
| Productname | Turpentine Liniment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Casnumber | 8006-64-2 |
| Molecularformula | C10H16 (approximate, mainly terpenes) |
| Molecularweight | 136.24 g/mol (approximate alpha-pinene basis) |
| Appearance | Clear, colorless to pale yellow viscous liquid |
| Odor | Characteristic penetrating, aromatic turpentine odor |
| Solubility | Soluble in alcohol, ether, chloroform, and fixed oils; practically insoluble in water |
| Specificgravity | 0.855 to 0.865 at 25°C |
| Refractiveindex | 1.465 to 1.478 at 20°C |
| Opticalrotation | -10° to +10° depending on source |
| Boilingpoint | Approximately 150°C to 180°C |
| Flashpoint | Approximately 35°C (closed cup) |
| Storage | Store in well-filled, airtight, light-resistant containers, away from heat and ignition sources |
| Shelflife | 24 months if stored under recommended conditions |
| Therapeuticcategory | Rubefacient, counter-irritant, and veterinary topical analgesic |
| Suggesteddosageforms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
As an accredited Turpentine Liniment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied in sealed, light-protected containers (25 kg) with tamper-evident closures, ensuring stability and safety for veterinary pharmaceutical formulations. |
| Container Loading (20′ FCL) | 20′ FCL: palletized, sealed drums of veterinary-grade turpentine liniment API, secured with proper ventilation, labeling, and temperature controls for safe transit. |
| Shipping | Shipment of Turpentine Liniment Veterinary Grade API occurs in sealed, light-resistant containers and suitable drum capacities, protected from moisture and heat. Store at controlled room temperature, away from flames/sparks. Transport complies with hazardous goods regulations (IATA/IMDG/ADR, Class 3) with proper labeling, documentation, and handling protocols. Custom packaging available. |
| Storage | Store Turpentine Liniment Veterinary Grade API in tightly sealed, original containers under cool, dry, well-ventilated conditions. Protect from direct sunlight, heat, sparks, and flames. Keep away from oxidizing agents and incompatible materials. Ensure containers remain upright to prevent leakage. Follow local hazardous material regulations and maintain proper labeling, with secure storage in a dedicated, locked area. |
| Shelf Life | Shelf life is typically 3 years when stored in tightly sealed, light-resistant containers under cool, dry conditions, per manufacturer specifications. |
During the manufacture of veterinary tablets and capsules, turpentine liniment veterinary grade is seldom compacted as a neat liquid API because direct compression of a volatile terpene fraction leads to oil migration, capping, and surface filming. The API is first adsorbed onto a dry carrier bed of microcrystalline cellulose, such as Avicel PH-102, and colloidal silicon dioxide in a high-shear granulator or ribbon blender. Liquid-to-carrier mass ratios of 1:3 to 1:5 are used for tablet adsorbates, while hard gelatin capsule fills commonly start at 1:2 to 1:4; the practical ratio is controlled by the oil absorption capacity of the carrier rather than by nominal active content. Carriers should be pre-dried when ambient relative humidity exceeds 60%, because residual moisture above 3% w/w reduces terpene adsorption and produces agglomeration during screening. Lactose monohydrate is not used as the sole carrier, as its surface moisture and reducing sugar groups can interact with terpene oxidation products and alter dissolution performance. The milled adsorbate is passed through a 0.8 mm screen and blended with crospovidone at 2–5% w/w and sodium stearyl fumarate at 0.5–1.0% w/w. Tableting on a rotary press with a maximum main compression force of 8–15 kN produces tablets with hardness of 60–90 N; higher compaction pressure can rupture the porous carrier and release oil at the tablet surface during storage. Disintegration is evaluated according to USP <701> and friability according to USP <1216>. Capsule filling is performed at not more than 40% RH, and finished capsules are packaged in cold-form aluminium blisters with a water vapour transmission rate below 0.5 g/m²/day; oxidative degradation products of α-pinene and β-pinene can crosslink gelatin and delay dissolution in unprotected packaging.
Water-miscible co-solvent systems alone cannot dissolve the terpene hydrocarbons of turpentine liniment veterinary grade at injectable concentrations; the API remains a separate oil phase with density of 0.854–0.870 g/mL at 20 °C and flash point 35–46 °C. Injectable formulations therefore use non-aqueous vehicles such as ethyl oleate, medium-chain triglycerides, or benzyl benzoate. Dissolution is carried out in jacketed stainless steel vessels at 25–30 °C under nitrogen, at an API concentration of 5–20% w/w where the target-species safety dossier supports parenteral use. Terminal moist-heat sterilization is generally avoided because the terpene flash point overlaps the saturated steam sterilization window; dry heat at 160 °C for 2 h may be used only after the vehicle and API show no increase in peroxide value above the release limit. The preferred sterilizing-grade approach is membrane filtration through 0.22 µm PTFE or PVDF filters into sterile amber Type I glass vials. Peroxide content is determined according to Ph. Eur. 2.5.5 method A and controlled at ≤10 meq O₂/kg for non-aqueous injectables. Bacterial endotoxin limits are calculated from the maximum intended dose according to USP <85> and Ph. Eur. 2.6.14. For parenteral emulsions, droplet size analysis by dynamic light scattering or laser diffraction is required, with mean droplet size below 500 nm per USP <729>; published data for commercial terpene-based veterinary injectable emulsions is limited. Headspace oxygen is purged to below 2% v/v with nitrogen, and closures are ETFE-coated to reduce terpene sorption and extractables formation.
In feed premix manufacturing, the API is sprayed through a fixed spray bar onto a dry carrier such as defatted rice bran or wheat middlings in a horizontal paddle mixer; the API is added at 2–5% w/w and mixed until α-pinene content in 10 grab samples shows a coefficient of variation not exceeding 5%, after which the premix is diluted into final feed at 0.5–2 kg/tonne under national veterinary feed rules such as Regulation (EU) 2019/4 or equivalent.
Topical rubefacient liniments are the most established downstream dose form in which the API is processed without prior solidification. In traditional soap-emulsified systems, oleic acid is dissolved in the terpene fraction at 2.5–7.5% w/w, and the resulting oil phase is neutralized with strong ammonia solution 25% w/w until a stable oil-in-water emulsion is obtained. Final turpentine oil concentrations in veterinary liniments are commonly within 10% v/v to 30% v/v; concentrations above this window increase rubefaction but require target-species dermal tolerance data. In a jacketed low-shear vessel with an anchor stirrer, mixing speed is maintained at 30–60 rpm, and the aqueous phase is added at a rate below 5% of batch volume per minute to prevent phase inversion and free-oil separation. During ammonia neutralization, batch temperature is kept below 30 °C to limit premature volatilization of free ammonia and to keep the system below the flash point. A high-shear rotor–stator homogenizer is used only for the initial concentrate; final dilution is completed under low-shear agitation to avoid droplet size reduction that increases viscosity beyond the target. The finished liniment is adjusted to pH 8.0–9.5, which maintains fatty-acid soap emulsification while limiting alkali-induced irritation. Brookfield viscosity at 20 °C, spindle 2 at 20 rpm, usually falls between 100–500 mPa·s. Filling into HDPE bottles requires fluorinated or barrier-lined containers because terpene hydrocarbons migrate into unmodified polyethylene over storage periods longer than 12 months. Stability is checked by centrifugation at 3000 rpm for 30 min; no more than 2% free-oil separation is considered acceptable for batch release. The product is not sterile-filtered because the emulsion is coarse; raw material bioburden control and species-suitable preservation are applied instead.
Representative starting compositions for topical liniment dispersion trials are shown below; they are development benchmarks, not regulatory limits.
| Component | Concentrate | Standard | Dilute |
|---|---|---|---|
| Turpentine liniment API (% v/v) | 30 | 20 | 10 |
| Oleic acid (% w/w) | 7.5 | 5.0 | 2.5 |
| Strong ammonia solution 25% (% w/w) | 3.0 | 2.0 | 1.0 |
| Deionized water q.s. to (mL) | 100 | 100 | 100 |
| Target pH window | 9.0–9.5 | 8.5–9.0 | 8.0–8.5 |
| Brookfield viscosity at 20 °C (mPa·s) | 350–500 | 200–300 | 100–180 |
For oral drench and drinking-water concentrates, the API is formulated as an emulsified concentrate rather than a simple solution. A cold-processable nonionic emulsifier pair of polysorbate 80 and sorbitan monooleate is adjusted to an effective HLB of 10–14; the terpene fraction is first dissolved in propylene glycol or glycerol formal at 10–25% w/w. The aqueous phase is added under high-shear rotor–stator mixing at 3,000–5,000 rpm, and butylated hydroxytoluene is added at 0.01–0.05% w/w to suppress oxidative degradation. The drench is filled into amber glass or barrier HDPE and should maintain viscosity below 100 mPa·s at 20 °C to allow consistent flow through calibrated drenching guns. Uniformity is checked by α-pinene assay on top, middle, and bottom samples after 24 h; a relative standard deviation of ≤5% indicates acceptable emulsion stability for batch release.
Where a sustained-release oral product is required, the API is first emulsified with an aqueous solution of maltodextrin and gum arabic and homogenized at 10,000–15,000 rpm. The emulsion is spray-dried at an inlet air temperature not exceeding 140 °C, because the terpene fraction oxidizes rapidly above 60 °C and volatile loss rises close to its flash point. The resulting powder is blended with hydroxypropyl methylcellulose and ethylcellulose, then extruded through a twin-screw extruder having an L/D ratio of 40:1, a barrel temperature profile of 30–70 °C, and die apertures of 0.5–1.0 mm. Spheronization yields pellets with sphericity greater than 0.9. The pellets are coated in a Wurster bottom-spray fluid bed with 5–10% w/w ethylcellulose to provide diffusion-controlled release over 8–12 h in surfactant-modified dissolution media. Release is measured using USP <711> apparatus 2 at 50 rpm, with sodium lauryl sulfate added to the medium because the API has low aqueous solubility. Process yield above 90% requires inlet air dew point below 8 °C and coating chamber relative humidity below 45%; excursions cause spheronizer screen blockages and loss of the terpene fraction.
Competitive Turpentine Liniment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Model TVG-LIN-API-37 identifies a rectified turpentine liniment active pharmaceutical ingredient intended for incorporation into seven veterinary dosage presentations: tablets, injections, capsules, powders, granules, premixes, and solutions. The liquid concentrate is standardised to the bicyclic monoterpene fraction, predominantly α-pinene and β-pinene, with camphene, limonene, and Δ³-carene present in comparatively minor quantities. The API is supplied as a clear, mobile, oxidisable liquid with a characteristic terpenic odour; batch certificates report relative density, refractive index, acid value, peroxide value, and residue on evaporation. The model designation is manufacturer-specific and should not be interpreted as a harmonised pharmacopoeial title; there is no single monograph covering turpentine liniment in all listed veterinary dosage forms. Where pharmacopoeial guidance is available, the closest raw material monograph is Turpentine Oil, Pinus pinaster type, and relevant general methods are applied.
Compendial acceptance criteria for the closest raw material specify α-pinene content within 70–85% and β-pinene content within 10–20%, depending on the declared Pinus species and chemotype. Solvent-grade turpentine, by contrast, is sold on total terpene content only; it may contain sulfur compounds, cis- and trans-pinane, and high-boiling residue that are not controlled for veterinary administration. Veterinary API-grade material is additionally controlled for peroxide value because α-pinene autoxidation generates pinene oxide and verbenyl hydroperoxide, which are potential sensitising impurities. Acid value is limited to 1.0 mg KOH/g or lower to exclude oxidised resin acids. The product specification therefore adds safety metrics that technical grades rarely report.
| Parameter | Veterinary API grade | Technical solvent grade | Reference method |
|---|---|---|---|
| Relative density at 20 °C | 0.854–0.868 g/cm³ | 0.850–0.900 g/cm³ | Ph. Eur. 2.2.5 |
| Refractive index at 20 °C | 1.465–1.478 | often unspecified | Ph. Eur. 2.2.6 |
| Acid value | ≤1.0 mg KOH/g | 2–5 mg KOH/g possible | Ph. Eur. 2.5.1 |
| Peroxide value | ≤10 meq O₂/kg | not specified | Ph. Eur. 2.5.5 |
| Residue on evaporation | ≤0.5% | 1–3% | Ph. Eur. 2.8.13 |
For tablet and capsule applications, the API is typically dispersed onto a porous carrier before blending. Fumed silica with a specific surface area of 200 ± 25 m²/g is charged first, and the liquid concentrate is metered through a 0.8 mm two-fluid nozzle at 0.5–1.0 kg/min into a high-shear mixer. The adsorption endpoint is reached when the tapped bulk density stabilises at 0.35–0.45 g/cm³ and the loss on drying at 60 °C for 15 min remains below 0.5%. Direct compression blends containing 1.5–3.0 wt% adsorbed API exhibit acceptable ejection force below 10 kN on a 10-station instrumented tablet press using 9 mm round flat-faced bevel-edge tooling. Exceeding 5.0 wt% loading without additional carrier increases capping incidence and punch filming because the terpene phase lowers particle-particle bonding strength. Capsule filling of the adsorbed powder is performed on a dosator or tamping-pin machine; the powder bed is conditioned to 30–45% relative humidity because low-moisture terpene adsorbates can generate static charges, and fill weight is controlled within ±5% of target for size 1 or size 0 capsules depending on bulk density.
Wet granulation of adsorbed turpentine liniment requires careful control of both mechanical and thermal input. The monoterpene pool begins to volatilise rapidly above 40 °C, and the closed-cup flash point is approximately 35 °C; therefore granulator jackets are maintained at 25–30 °C and the bowl is purged with nitrogen when the liquid fraction is introduced. Aqueous granulation is not preferred for unprotected API, but addition of the adsorbed powder to an ethanolic povidone K30 binder solution produces granules with bulk density 0.45–0.55 g/cm³ and Hausner ratio below 1.35. Drying is conducted in a fluid-bed dryer at inlet air temperature 35 °C and dew point ≤5 °C until loss on drying is below 0.5%. Long-term contact with oxygen attacks the unsaturated bicyclic structure; inert headspace storage is specified for intermediate bulk containers, and stainless steel 316L or high-density polyethylene contact surfaces are preferred. Iron and copper must be avoided because they accelerate peroxide formation.
Published data for injectable veterinary formulations of turpentine liniment API are limited. In aqueous parenteral systems, the monoterpene fraction is poorly miscible; a co-solvent system of 10–20 v/v% dehydrated ethanol and 30–40 v/v% propylene glycol, with 1–2 v/v% polysorbate 80, is required to maintain a submicron droplet distribution after sterile filtration. Terminal filtration through 0.22 µm PVDF membranes is preferred over polyamide, because terpene-rich oils cause polyamide swelling and potential particulate shedding. No harmonised veterinary monograph currently defines a quantitative dissolution or endotoxin limit for this specific API in injectable presentations; release is therefore governed by the manufacturer’s target product profile and ICH Q3D elemental impurity limits appropriate to the parenteral route. Process capability for oxygen-sensitive parenteral emulsions requires dissolved oxygen below 0.5 mg/L in the aqueous phase before homogenisation.
For feed premix and granulated premix presentations, the primary processing objective is blend uniformity under high dilution. The adsorbed API is mixed with milled limestone or rice hull carrier in a double-cone blender at 60% fill volume and 25 rpm for 10 min. Blend uniformity is confirmed by gas chromatography of α-pinene in ten sampling ports; acceptance is relative standard deviation ≤5.0% per USP <905>. The final premix may contain 0.1–1.0 wt% active monoterpene fraction depending on the target species, body weight, and intended daily feed intake. Published dose-response data for turpentine liniment in feed-based veterinary premix is limited, so inclusion levels are derived from historical topical liniment doses and are not substitutable across species.
Food-grade terpene isolates such as d-limonene or α-pinene fractions are often obtained by fractional distillation under vacuum and are sold with high chemical purity. However, food-grade status does not automatically confer veterinary API acceptability; food-grade specifications generally omit microbial enumeration, viral safety, endotoxin control for parenteral use, and residual solvent classification under VICH GL18/R. Technical pine oil used in cleaning and solvent applications contains higher levels of high-boiling residue, sulfur compounds, and water, and may be deliberately blended with surfactants that are not acceptable for pharmaceutical manufacture. Veterinary-grade turpentine liniment API is therefore differentiated by its compliance matrix: identity by gas chromatography with headspace injection, assay of total bicyclic monoterpenes, peroxide and acid limits, elemental impurities under ICH Q3D, residual solvents under VICH GL18/R, and microbial examination per Ph. Eur. 5.1.4.
| Quality attribute | Acceptance limit | Reference standard or method |
|---|---|---|
| Total bicyclic monoterpenes, α-pinene + β-pinene peak area | ≥80% of total terpene peak area | GC-FID, headspace injection |
| Residual solvents | Class 3 only; individual solvent ≤0.5% w/w | VICH GL18/R |
| Elemental impurities | ICH Q3D Option 1 limits for intended route | ICH Q3D |
| Total aerobic microbial count | ≤10³ CFU/g | Ph. Eur. 5.1.4 |
| Total yeast and mould count | ≤10² CFU/g | Ph. Eur. 5.1.4 |
| Escherichia coli | absent in 1 g | Ph. Eur. 5.1.4 |
The API is packaged in nitrogen-flushed amber glass bottles or epoxy-phenolic lined steel drums. Closure integrity is maintained to exclude oxygen and moisture; storage below 25 °C and relative humidity below 60% is specified. Under these conditions, the retest period is assigned from accelerated stability data at 40 ± 2 °C and 75 ± 5% relative humidity per VICH GL3; published data for this exact liniment matrix is limited, so real-time data governs the assigned shelf life. The material is transported as UN 1299, Class 3, packing group III; local flammable liquid handling requirements apply.
Solution dosage forms require the lowest process intensity. The API is dissolved or diluted into rectified light liquid paraffin or isopropyl myristate at 5–20% v/v for topical veterinary liniments. For oral solutions, ethanol or propylene glycol may be required to improve miscibility; final fill volume is adjusted after recirculation through a 0.45 µm membrane. Viscosity at 25 °C remains below 50 mPa·s for light liquid paraffin-based liniments; turbidity is monitored at 600 nm and should remain below 10 NTU after 24 h at 5 °C. The differences from other turpentine products therefore lie not in core terpene content alone, but in the controlled reduction of oxidised, microbial, heavy metal, residual solvent, and high-boiling residue burdens required for pharmaceutical veterinary use across solid, liquid, and parenteral presentations.
